

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 20, 2003, 01:47:25 ; Search time 237 Seconds
(without alignments)
5311.675 Million cell updates/sec

Title: US-09-867-958-2

Perfect score: 559
Sequence: 1 ccgcacatgcacgcgcgcacac.....cgctcagccttgcgcgcg 559

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database :

N.Geneseq_101002:*

1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	559	100.0	559	20	AAK36136
2	549.4	98.3	1006	22	AAI58712
3	434.6	77.7	1859	22	AAK55488
4	432.2	77.3	1869	22	AAI58813
5	381.8	68.3	1074	22	AAI60498
6	103	18.4	2007	24	ABO58445
7	102.6	18.4	764	22	AAI97619
8	101.2	18.1	483	22	AAH43100
9	94.2	16.9	569	24	ABO58935

10	94.2	16.9	664	24	ABO57521	Human colon cancer
11	93	16.6	570	24	ABU37927	Human colon tumour
12	84.4	15.1	575	24	ABO59145	Human colon cancer
13	82.6	14.8	561	24	ABO58126	Human colon cancer
14	75.2	13.5	473	24	ABK09599	Human ovarian tumor
15	65.4	11.7	471	24	ABN88218	Human colon cancer
16	56.6	10.1	1776	24	ABU39694	Human NS cDNA sequ
17	54.4	9.7	314	22	AAE84993	Nucleic acid sequ
18	50.4	9.0	477	21	AAE21984	Human breast and o
19	48.8	8.7	447	21	AAI82544	Human polynucleoti
20	45.2	8.1	587	21	AAO6253	Human secreted pro
21	39	7.0	441	23	ABY17722	Human prostate exp
22	39	7.0	497	23	ABY47515	Human prostate exp
23	38.2	6.8	2418	23	ABU03387	Drosophila melanog
24	38.2	6.8	4204	23	ABU04694	Drosophila melanog
25	38.2	6.8	4477	23	ABU03386	Drosophila melanog
26	35.2	6.3	301	24	ABK93035	CDNA encoding huma
27	35.2	6.3	3929	23	AAU70024	DNA encoding novel
28	35.2	6.3	3393	16	AAU03885	Human mucosal lymph
29	34.6	6.2	467	22	ABA51936	Human foetal liver
30	34.6	6.2	467	22	ABA21751	Probe #217 for
31	34.6	6.2	467	22	AAK00225	Human brain exp.
32	34.6	6.2	467	22	AAK25668	Human bone marrow
33	34.6	6.2	467	22	AAI10295	Probe #228 for gen
34	34.6	6.2	467	22	AAI31544	Probe #230 used to
35	34.6	6.2	467	22	AAI00231	Probe #222 used to
36	34.6	6.2	467	24	ABU00240	Human genome-deriv
37	34.6	6.2	1186	22	ABA46719	Human breast cell
38	34.6	6.2	1186	22	ABA64595	Human foetal liver
39	34.6	6.2	1186	22	ABA31721	Probe #10187 for g
40	34.6	6.2	1186	22	AAK13036	Human brain expres
41	34.6	6.2	1186	22	AAK38767	Human bone marrow
42	34.6	6.2	1186	22	AAI19573	Probe #9506 for ge
43	34.6	6.2	1186	22	AAI44765	Probe #13451 used
44	34.6	6.2	1186	22	AAI05293	Probe #5284 used t
45	34.6	6.2	1186	24	ABU12841	Human genome-deriv

ALIGNMENTS

RESULT 1	
AAK36136	
ID	AAK36136 standard; DNA; 559 BP.
XX	
AC	AAK36136;
XX	
DT	19-JUL-1999 (first entry)
XX	
DE	DNA encoding a human progesterone receptor complex p23-like protein.
XX	
KW	Human progesterone receptor complex p23-like protein; PR23P;
KW	neurological disorder; antagonist; reproductive disorder;
KW	immunological disorder; neoplastic disorder; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO9919483-A1.
XX	
PD	22-APR-1999.
XX	
PF	09-OCT-1998; 98WO-US21402.
XX	
PR	09-OCT-1997; 97US-0948197.
XX	
PA	(INCY-) INCYTE PHARM INC.
XX	
PI	Corley NC, Shah P, Yue H;
XX	
DR	WPI; 1999-302530/25.
DR	P-PSDB; AAY02591.
XX	
PT	Human progesterone receptor complex p23-like protein

XX Claim 7; Fig 1A-B; 67bp; English.

CC The present sequence encodes a human progesterone receptor complex
 CC p23-like protein (PR23p). PR23p is used to treat neurological
 CC disorders. Antagonists of PR23p are useful for treating reproductive,
 CC immunological or neoplastic disorders. Probes and primers based on the
 CC PR23p polynucleotides can be used for diagnosis, detection and screening
 CC of homologues, and amplification of PR23p genes. Antisense PR23p
 CC polynucleotides can be used to decrease or inhibit expression of PR23p.

XX Sequence 559 BP; 140 A; 114 C; 165 G; 140 T; 0 other;

Query Match 100.0%; Score 559; DB 20; Length 559;

Best Local Similarity 100.0%; Pred. No. 4.6e-171; Mismatches 0; Gaps 0;

Matches 559; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CCGCAATGCGACGCGACGCCGACCTTGCTAGACAGAGCCCATGTATGTGTCA 60
 DB 1 CCGCAATGCGACGCGACGCCGACCTTGCTAGACAGAGCCCATGTATGTGTCA 60
 QY 61 TGGAGTTTGTGTGAGACAGCACCATGTCCACGCTTATGAGATCACCGCATTG 120
 DB 61 TGGAGTTTGTGTGAGACAGCACCATGTCCACGCTTATGAGATCACCGCATTG 120
 QY 121 TGTTCAGCTGCAGAAATGCCATGGATGGATGTACAAATGATGCTATGGCA 180
 DB 121 TGTTCAGCTGCAGAAATGCCATGGATGGATGTACAAATGATGCTATGGCA 180
 QY 181 AAGTGAAGTCCAGAGACTCCAGAGATAAGCGCTCTCCGCTCTATTAATTGTTGTA 240
 DB 181 AAGTGAAGTCCAGAGACTCCAGAGATAAGCGCTCTCCGCTCTATTAATTGTTGTA 240
 QY 241 GAAATGGAAGAAAGTGGCTGGCGCGGCTTACCAAGAGATATCAAGCCAGTGT 300
 DB 241 GAAATGGAAGAAAGTGGCTGGCGCGGCTTACCAAGAGATATCAAGCCAGTGT 300
 QY 301 GGCTGTCTGTGACTTTGATTAAGTGAAGAGACTGGGAAGGGATGAAGATGAGCTGG 360
 DB 301 GGCTGTCTGTGACTTTGATTAAGTGAAGAGACTGGGAAGGGATGAAGATGAGCTGG 360
 QY 361 CTCATGTGGAACATTATGACAGAGCTTTTGAAGAAAGTGCAGCAACAGAGACCTCCACCTG 420
 DB 361 CTCATGTGGAACATTATGACAGAGCTTTTGAAGAAAGTGCAGCAACAGAGACCTCCACCTG 420
 QY 421 CCATGATGATTTGGATGATATTTCTGACATGCTGATGATGCAACAAGTAATTAATT 480
 DB 421 CCATGATGATTTGGATGATATTTCTGACATGCTGATGATGCAACAAGTAATTAATT 480
 QY 481 CTGTGAGCAAGAGCTGGGAAGAGCAAGCTGTGCTATTTTCCAGTTGTTAGAAAAGCTAGC 540
 DB 481 CTGTGAGCAAGAGCTGGGAAGAGCAAGCTGTGCTATTTTCCAGTTGTTAGAAAAGCTAGC 540
 QY 541 GCCTAGGCGCTTTGTTCAGCG 559
 DB 541 GCCTAGGCGCTTTGTTCAGCG 559

RESULT 2
 ID AA158712 standard; cDNA; 1006 BP.
 XX AA158712;
 AC
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polynucleotide SEQ ID NO 915.
 KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;

KM Leukemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000WO-US34263.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 XX
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 PA (HSE-) HYSEQ INC.
 XX
 PI Tang YF, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao Q, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI: 2001-442253/47.
 DR P-PSDB: AAM39556.
 XX
 PT Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 PS Claim 1; SEQ ID NO 915; 10078bp; English.
 XX
 CC The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AAM38642-AA42213) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: immune system suppression,
 CC activation/inhibition activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the prior
 CC art.
 XX
 SQ Sequence 1006 BP; 235 A; 244 C; 265 G; 262 T; 0 other;

Query Match 98.3%; Score 549.4; DB 22; Length 1006;
 Best Local Similarity 99.8%; Pred. No. 8.4e-168;
 Matches 550; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CCGCAATGCGACGCGACGCCGACCTTGCTGACAGAGCCCATGTATGTGTCA 60
 DB 360 CCGCAATGCGACGCGACGCCGACCTTGCTGACAGAGCCCATGTATGTGTCA 419
 QY 61 TGGAGTTTGTGTGAGACAGCACCATGTCCACGCTTATGAGATCACCGCATTG 120
 DB 420 TGGAGTTTGTGTGAGACAGCACCATGTCCACGCTTATGAGATCACCGCATTG 479
 QY 121 TGTTCAGCTGCAGAAATGCCATGGATGGATGTACAAATGATGCTATGGCA 180
 DB 480 TGTTCAGCTGCAGAAATGCCATGGATGGATGTACAAATGATGCTATGGCA 539
 QY 181 AAGTGAAGTCCAGAGACTCCAGAGATAAGCGCTCTCCGCTCTATTAATTGTTGTA 240
 DB 540 AAGTGAAGTCCAGAGACTCCAGAGATAAGCGCTCTCCGCTCTATTAATTGTTGTA 539
 QY 241 GAAATGGAAGAAAGTGGCTGGCGCGGCTTACCAAGAGATATCAAGCCAGTGT 300

Db 600 GAAATGAGAGAAAGGTGGCGCTGGCCGGCTTACCAAGAGATATACAGCCAGTGT 659
QY 301 GCGTGTCTGTGACTTTGATATACTGGAGAGACTGGGAAAGGGATGAAGATGGAGCTGG 360
Db 660 GGGCTGTCTGTGACTTTGATATACTGGAGAGACTGGGAAAGGGATGAAGATGGAGCTGG 719
QY 361 CTGATGTGAGCAATTATTCAGAGCTTTTGAAGAAGTACGACCAAGAGACTCCACCTG 420
Db 720 CTCATGTGGAACATTATTCAGAGCTTTTGAAGAAGTACGACCAAGAGACTCCACCTG 779
QY 421 CCATGATGATTTGGATGATGATTTCTGACAGTCTGATGATGATGATGATGATTAATTAATT 480
Db 780 CCATGATGATTTGGATGATGATTTCTGACAGTCTGATGATGATGATGATGATTAATTAATT 839
QY 481 CTGTGAGCAAGCTGGGAGAGCAAGCTGGCTATTTCCAGTGTCTTGAAGAAGTACG 540
Db 840 CTGTGAGCAAGCTGGGAGAGCAAGCTGGCTATTTCCAGTGTCTTGAAGAAGTACG 899
QY 541 GCGTAGGCGCTT 551
Db 900 GCGTAGGCGCTT 910

RESULT 3
AAK5488
ID AAK5488 standard; cDNA; 1859 BP.
XX AAK5488;
AC AAK5488;
XX
DT 06-NOV-2001 (first entry)
DE Human immune/haematopoietic antigen encoding cDNA SEQ ID NO:548.
XX
XX Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KM cytostatic; gene therapy; vaccine; metastasis; ss.
XX
OS Homo sapiens.
XX
PN W0200157182-A2.
XX
PD 09-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US01354.
PF
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 11-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.

PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 03-SEP-2000; 2000US-0229309.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 21-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.

Sequence 1859 BP; 461 A; 422 C; 567 G; 405 T; 4 other;

Matches	434;	Conservative	2;	Mismatches	1;	Indels	0;
---------	------	--------------	----	------------	----	--------	----

Db 596 CCATGGATGATTGGAT 612

ID	AAI58813 standard; CDNA; 1869 BP.

AC AAI58813;

DT 22-OCT-2001 (first entry)
 XX

Human polynucleotide SEQ ID NO 1016.

KW Leukaemia; ss

OS Homo sapiens.

PN WO200153312-A1.

PD 26-JUL-2001.

PF 26-DEC-2000; 2000WO-US34263.
VY

PR 21-JAN-2000; 2000US-0488725.
DB 3E-APR-2000 0000US-0553317

PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0630313

PR	03-AUG-2000;	2000US-0653450.
PR	14-SEP-2000;	2000US-0663191

PR 19-NOV-2000: 2000TS-0727344

AA
PA (HYSE-) HYSEO INC

[illegible]

XX PN WO200166719-A1.
 XX PD 13-SEP-2001.
 XX PF 02-MAR-2001; 2001WO-JP01629.
 XX PR 07-MAR-2000; 2000JP-0159195.
 XX PA (CHIB-) CHIBA PREFECTURE.
 XX PA (HISM) HISAMITSU PHARM CO LTD.
 XX PI Nakagawara A.
 XX DR WPI; 2001-565584/63.
 XX PT Nucleic acids originating in gene expressed in human neuroblastoma,
 PT useful as probe or primer in diagnosing prognosis of human
 PT neuroblastoma, malignancy and susceptibility indicator or tumour marker
 PT for anti-cancer agents.
 XX PS Claim 1; Page 2680-2681; 2979pp; Japanese.
 XX CC The invention relates to novel genes (AA193926-AA197963) expressed in
 CC human neuroblastoma. The nucleic acids are applicable as a probe or
 CC primer in diagnosing the prognosis of human neuroblastoma, malignancy and
 CC susceptibility indicators or tumour markers for anti-cancer agents. The
 CC gene information for diagnosing prognosis is related to factors similar
 CC to that for N-myc and TrkA genes.
 XX SQ Sequence 764 BP; 229 A; 150 C; 192 G; 189 T; 4 other;

Query Match 18.4%; Score 102.6; DB 22; Length 764;
 Best Local Similarity 55.4%; Pred. No. 1.1e-22;
 Matches 220; Conservative 0; Mismatches 174; Indels 3; Gaps 1;
 OY 1 CCGGAATGGCAGCGCAGACGCCGACCTTGTGTACAGACGCCCATGTATGCTTCA 60
 DB 207 CCGCGTTCACAAATGCAGCTCTCTTCCAAAGTGTAGAGAGAGGAGGACTATGCTTCA 266
 OY 61 TGAAGTTTGTGTGAGAGACACCGATGTCACAGCTTATGAGATCCACCGATG 120
 DB 267 TGTGATTTTGTGTGAGAGACAGATGATGTTAATGTAATTTTAAATCCAAACTTA 326
 OY 121 TGTGACCTGCAAGATGCC--GATGAGTGTGAGTGTACATGATGATGATGATG 177
 DB 327 CATTCAGTTGTCTGAGAGAGATGATTAATTAACATTTAATGAATGATCTTTTC 386
 OY 178 CCAAGTGAATCCCAAGGACTCCCAAGATTAACCGCTCTTCCGCTCTATTTACTGTTTG 237
 DB 387 ACTGTATGATCCAAATGATTCCAAGCATTAAGAACGACATCAATTTATGTTGT 446
 OY 238 TGAAGATGAAGAAAGATGAGCTGCGCGCGCTTACCAAGAGATATCAAGCCAG 297
 DB 447 TACGAAAGAGGATCTGCGCCAGTCATGCGGATTAACAAAGAGGCGCAAGCTTA 506
 OY 298 TGTGCTGTCTGTGAGCTTTGATTAAGTGTGAGAGACTGTGGAAGGAGATGATGAGC 357
 DB 507 ATTGGCTTAATGTGATGATCAATTAATTTGAAAGACTGGAAGATATTCAGATGAAGACA 566
 OY 358 TGGCTCATGTGAACATTATGCAAGACTTTTGAAGAA 394
 DB 567 TGTCTAATTTTGAATCGTTTCTGTGAGATGATGAACAA 603

RESULT 8
 AAH43100
 ID AAH43100 standard; DNA; 483 BP.
 XX AAH43100;
 AC
 XX
 DT 15-OCT-2001 (first entry)
 XX

DE Nucleotide sequence of a human prostaglandin E1 (PGE1) synthase.
 XX Human; prostaglandin E1 synthase; PGE1 synthase; arachidonic acid;
 KW inflammation; ss.
 XX Homo sapiens.
 XX Key Location/Qualifiers
 FH CDS 1..483
 FT /tag= a
 FT /product= "prostaglandin E1 (PGE1) synthase"
 XX WO200157225-A1.
 XX PD 09-AUG-2001.
 XX PF 25-AUG-2000; 2000WO-JP05758.
 XX PR 03-FEB-2000; 2000JP-0032704.
 XX PA (CHUS) CHUGAI SEIYAKU KK.
 XX PA (KUDO/) KUDO I.
 XX PI Kudo I, Murakami M, Ohishi S;
 XX WPI; 2001-483439/52.
 XX P-PSDB; AA63379.
 PT PGE2-1 protein and encoded gene with PGE2 synthase activity, useful in
 PT screening efficient PGE2 synthase inhibitors as antiinflammatory agents
 PT
 PS Disclosure; Fig 5; 54pp; Japanese.
 XX The present sequence encodes a human prostaglandin E1 (PGE1) synthase.
 CC The protein synthesizes PGE2 from arachidonic acid in consort with COX.
 CC The PGE2 synthase protein and gene are useful in screening for efficient
 CC PGE2 synthase inhibitors. These inhibitors are useful as
 CC anti-inflammatory agents.
 XX SQ Sequence 483 BP; 166 A; 63 C; 114 G; 140 T; 0 other;

Query Match 18.1%; Score 101.2; DB 22; Length 483;
 Best Local Similarity 54.3%; Pred. No. 2.3e-22;
 Matches 252; Conservative 0; Mismatches 203; Indels 9; Gaps 2;
 OY 14 GCAGCAGCCCGGACCTTGTGTGAGCAGACGCCCATGTATGTTGATGAGATTTGTGT 73
 DB 3 GCAGCCTGCTTGTGCAAAAGTGTGACGATGGAAGGACATATGCTTCATTAATTTGTGT 62
 OY 74 TGAAGCAGCAGCAGGATGTCAGCTGCTTATGAGATCAACCGCATGTGTGTACAGTCCAA 133
 DB 63 TGAAGCAGCAGGATGATTAATGTAATTTTGAATAATTCAAACTTACATTCAGTGTCT 122
 OY 134 GAATGCC--GATGAGTGTGAGTGTGATGATGATGATGATGATGATGATGATGATG 190
 DB 122 CGGAGGAATGATTAATTTTAAGCATTTAATGAATGATTTTTCACAGTATGATCC 182
 OY 191 CAGGACATCCCAAGATTAACGCTCTTCCGCTCTATTTACTGTTTGTGAGAAATGGA 250
 DB 183 AATGATTTCCAGCATTAATAAGAAAGACAGATCAATTTATGTTGTTACGAAAGAGAGA 242
 OY 251 GGAAGAGTGGCTGCGCGCGCTTCCCAAGAGGATATCAAGCCAGTGTGTGTCTGT 310
 DB 243 ATCTGGCCAGTATGCGCAAGGTTAAACAAAGAGGAGCAAACTTAATTTGGTGTAGT 302
 OY 311 GGACTTTGATTAAGTGTGAGAGTGTGGAAGGAGTGAAGATGAGTGTGATGATGGA 370
 DB 303 CGACTTCATTAATTTGGAAGAGTGTGGAAGATGATTAATGATGAAGACATGTCTTAATTTTGA 362
 OY 371 ACATTATGAGAGCTTTTGAAGAGTCAAG-----CACCAAGAGACTCCCACTGCCAT 424
 DB 363 TCGTTTCTCTGATGATGATGAACACATGCGGTGTGATGAGATGATGATTTACCAAGAG 422

Best Local Similarity 55.6%; Pred. No. 5.3e-20;
Matches 202; Conservative 0; Mismatches 158; Indels 3; Gaps 11

[illegible]

```

RESULT 11
ABL37927
ID ABL37927 standard; cDNA; 570 BP

```

AC ABL37927

DT 08-APR-2002 (first entry)

Human colon tumour antigen polynucleotide SEQ ID NO:1516.

KM Human; colon cancer; colon tumour antigen; cytostatic; vaccine;
KW colon tumour metastatic antigen; diagnosis; gene; ss.
VV

Homo sapiens.

PN W0200196388-A2

PD 20-DEC-2001.

PF 08-JUN-2001; 2001WO-US185557.
VY

PR 09-JUN-2000; 2000US-210899P.
PR 20-FEB-2001; 2001US-270216P.
XX

PA (CORI-) CORIXA CORP.

PI Jiang Y, Harlocker SL, Secr1st H;
 XY

DR WPI; 2002-114514/15.
XX

PT Novel isolated colon tumor polynucleotide differentially expressed in
PT colon tumor or colon metastatic tumor and polypeptides encoded by them
PT useful for inhibiting development of cancer in patient -

PS Claim 1; SEQ ID 1516; 105pp; English.
xx

CC specific for a tumour protein on contact with the T cells. They are also
CC production. (I) can be used for stimulating and/or expanding T cells
CC cDNA libraries. (I) have cytotoxic activity and can be used in vaccine
CC which were isolated from human colon tumour and colon metastatic tumour
CC AB13641 to AB13845 represent human colon tumour antigen cDNA clones (I)
CC

CC useful for inhibiting the development of cancer in a patient. (1) can be
CC used as probes or primers for nucleic acid hybridisation, for preparing
CC mutant species primers, or primers for use in genetic constructions. (1)
CC can be used in the diagnosis of a colon tumour.
XX
S0 Sequence 570 BP; 199 A; 73 C; 128 G; 167 T; 3 other;

SQ Sequence 570 BP; 199 A; 73 C; 128 G; 167 T; 3 other;

Query Match	16.6%	Score 93	DB 24	length 570
Best Local Similarity	54.6%	Pred. NO.	1.2e-19	
Matches 233	Conservative	0	Mismatches 185	Indels 9
				Gaps 2

OY 51 TATGTGTTAAGACGTTTTTGTTGAACAACCGANTCACCCTGGTTAATTGAGCAT 11
 || | | | | | | | | | | | | | | | |
Db 15 TAGCTCCTCAATTGAATTTGTTGTGAACACAGAAGATGTTAAATGATAATTTGAAAA 74

```

QY      111 CACCGCATTTGTTTCAGCTGCAGAAGATC---CCGATGGAGTGGAGTTGTACATGAGATT 16
          |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Db      75 TCCAAACTTACATTCAGTTGTCGCGAGGAGTGATAATTTTAAGCATTTAAATGAAATT 13

```

qy 168 GAGTTCATGACCAAGAATGAACCTCCAGATTAAGCGCTCTCCGCTCATTT
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 135 GATCTTTTCACTGTATTGATTCCAAATCATTTCCAAGCATTAAGAACGACAGATCAATT

228 ACCTGTTTGTGAGAAATGGAAGAAAAGTGGCCTGGCCGGCGCTTACCAAGAGCAT 28
 ||| | | |||| | | | |||| | | | |||
 Db 195 TTATGTTGTTACGAAAAGGAGATCTGGCCAGTCATGGCCCAAGGTTACCAAGAAGAG 25

255 GCAAGCTTAATTGGCTAGTCTCGACTTCAATTAATTGGAAGACATGGAGATGATCA 314

315 GAGGAGACATGTCATATTTCATCGTTCTCTGAGATGATGAACAACATGGGTGTCAT 374

Db 375 GAGGATGTAGG

RESULT 12
ABQ59145
ID ABQ59145 standard; cDNA; 575 BP

AC ABQ59145;

DT 02-AUG-2002 (first entry)

DE Human colon cancer related nucleotide sequence SEQ ID NO:2840.

Human; colon cancer; cancer; tissue profiling; forensic; mapping; denoising analysis; diagnostic; therapeutic; genomic

XX Homo sapiens

XX WO200229086-A2
PN

XX 11-APR-2002
PD

AA 02-OCT-2001; 2001WO-US30732.
PF

02-OCT-2000; 2000US-237271P.

PA (FARB) BAYER CORP

PI Burgess C, Astle JH, Carroll E, Catino TJ, Dwivedi P, Molino GA;

DR WPI; 2002-426115/45.

XX New isolated nucleic acid that is differentially expressed in cancer
 PT tissues useful for determining the presence of colon cancer in a cell
 PT or tissue type, and in antisense therapy

XX Claim 1; Fig 1; 796pp; English.

XX AB056306 to AB060787 represent isolated nucleic acids (I) differentially
 CC expressed in cancer tissues. AB078993 to AB079004 represent proteins
 CC encoded by the AB060776 to AB060787 nucleic acid sequences. (I) can be
 CC used in antisense therapy. An antibody immunoreactive with a polypeptide
 CC encoded by (I) is useful for detecting cancer in a patient sample, and
 CC for detecting the presence or absence of a polynucleotide encoded by a
 CC nucleic acid which hybridises to (I) in a cell. A probe/primer derived
 CC from (I) can be used for determining the presence of a nucleic acid which
 CC hybridises to (I), and for determining the phenotype of cells in a sample
 CC of cells from a patient. (I) is useful for determining the presence of
 CC colon cancer in a cell or tissue type, for determining the presence of
 CC state of other type of cancer, in antisense therapy, to generate
 CC macroarrays on a solid surface, to identify a chromosome on which the
 CC corresponding gene resides, and in tissue profiling, forensics, genetic
 CC analysis, mapping and diagnostic applications. (I) can be used to raise
 CC antibodies, and to screen for peptide analogues and antagonists.

XX Sequence 575 BP; 186 A; 72 C; 116 G; 179 T; 22 other;

XX Query Match 15.1%; Score 84.4; DB 24; Length 575;

XX Best Local Similarity 56.5%; Pred. No. 7.4e-17; Matches 196; Conservative 0; Mismatches 147; Indels 4; Gaps 2;

XX 51 TATGTTTCATGAGATTGTTGTTGAGACGACGACGATCCAGCTTATTTAGAGAT 110

XX 15 TATGTTTCATGAGATTGTTGTTGAGACGACGATCCAGCTTATTTAGAGAT 74

XX 111 CACCGATTGTGTCAGCTGCAAGATGCC--GATGAGCTGAGTTTCAATGAGATT 167

XX 75 TCCAACTTACATTCAGTTGCTCGGAGAGATGATTAATTTTAAAGATTAAATTA 134

XX 168 GAGTTTCATGCAAAAGTGAAGTCCAGGACTCCAGATTAAGGCTTCCGCTCATTT 227

XX 135 GATCTTTTTCACGTATTTGATTCCTCAATTCATTCAGCATTAAGAAAGGACATCATTT 194

XX 228 ACTGTTTGTGAGAAATGGAAGAAAGTGGCCCTGGCCGCGCTTACCAAGAGAT 287

XX 195 TTATGTTGTTAGAGAAAGAGAAATCTGGCCAGTCAATGGCCAAAGTAAAGAAAG 253

XX 288 ATCAAGCCAGTGTGCTGTGCTGACCTTGAATGAGAGACTGGGAAGGGGATGAA 347

XX 254 GCAAGCTTAATTTGGCTTGTAGTCGACTTCAATTAATTTGAAAGACGGAAGATGATTC 313

XX 348 GAGATGAGAGCTGGCTCATGTCGAACATTAATGACAGACTTTTGAAGAA 394

XX 314 GATGAAGACATGCTTAATTTTGTATCTTCTCGAGATGATGAACAA 360

XX RESULT 13

XX ID AB058126 standard; CDNA; 561 BP.

XX AC AB058126;

XX DT 02-AUG-2002 (first entry)

XX DE Human colon cancer related nucleotide sequence SEQ ID NO:1821.

XX KM Human; colon cancer; cancer; tissue profiling; forensic; mapping;

XX KW genetic analysis; diagnostic; antisense therapy; gene; ss.

XX OS Homo sapiens.

XX PN WO200229086-A2.

XX PD 11-APR-2002.

XX 02-OCT-2001; 2001WO-US030732.

XX 02-OCT-2000; 2000US-237271P.

XX (FARB) BAYER CORP.

XX Burgess C, Askle JH, Carroll E, Catino TJ, Dwivedi P, Molino GA;
 PI Thilagalingam A, Lewis ME;

XX WPI; 2002-426115/45.

XX New isolated nucleic acid that is differentially expressed in cancer
 PT tissues useful for determining the presence of colon cancer in a cell
 PT or tissue type, and in antisense therapy

XX Claim 1; Fig 1; 796pp; English.

XX AB056306 to AB060787 represent isolated nucleic acids (I) differentially
 CC expressed in cancer tissues. AB078993 to AB079004 represent proteins
 CC encoded by the AB060776 to AB060787 nucleic acid sequences. (I) can be
 CC used in antisense therapy. An antibody immunoreactive with a polypeptide
 CC encoded by (I) is useful for detecting cancer in a patient sample, and
 CC for detecting the presence or absence of a polynucleotide encoded by a
 CC nucleic acid which hybridises to (I) in a cell. A probe/primer derived
 CC from (I) can be used for determining the presence of a nucleic acid which
 CC hybridises to (I), and for determining the phenotype of cells in a sample
 CC of cells from a patient. (I) is useful for determining the presence of
 CC colon cancer in a cell or tissue type, for determining the presence of
 CC state of other type of cancer, in antisense therapy, to generate
 CC macroarrays on a solid surface, to identify a chromosome on which the
 CC corresponding gene resides, and in tissue profiling, forensics, genetic
 CC analysis, mapping and diagnostic applications. (I) can be used to raise
 CC antibodies, and to screen for peptide analogues and antagonists.

XX Sequence 561 BP; 192 A; 73 C; 128 G; 167 T; 1 other;

XX Query Match 14.8%; Score 82.6; DB 24; Length 561;

XX Best Local Similarity 54.6%; Pred. No. 2.8e-16; Matches 233; Conservative 0; Mismatches 184; Indels 10; Gaps 3;

XX 51 TATGTTTCATGAGATTGTTGTTGAGACGACGATCCAGCTTATTTAGAGAT 110

XX 14 TATGTTTCATGAGATTGTTGTTGAGACGACGATCCAGCTTATTTAGAGAT 73

XX 111 CACCGATTGTGTCAGCTGCAAGATGCC--GATGAGCTGAGTTTCAATGAGATT 167

XX 74 TCCAACTTACATTCAGTTGCTCGGAGAGATGATTAATTTTAAAGATTAAATGAAT 133

XX 168 GAGTTTCATGCAAAAGTGAAGTCCAGGACTCCAGATTAAGGCTTCCGCTCATTT 227

XX 134 GATCTTTTTCACGTATTTGATTCCTCAATTCATTCAGCATTAAGAAAGGACATCATTT 193

XX 228 ACTGTTTGTGAGAAATGGAAGAAAGTGGCCCTGGCCGCGCTTACCAAGAGAT 287

XX 194 TTATGTTGTTAGAGAAAGAGAAATCTGGCCAGTCAATGGCCAAAGTAAAGAAAG 253

XX 288 ATCAAGCCAGTGTGCTGTGCTGACCTTGAATGAGAGACTGGGAAGGGGATGAA 347

XX 254 GCAAGCTTAATTTGGCTTGTAGTCGCGCTTCAATTAATTTGAAAGACGGAAGATGATTC 312

XX 348 GAGATGAGAGCTGGCTCATGTCGAACATTAATGACAGACTTTTGAAGAAAGTCAAG-----C 401

XX 313 GATGAAGACATGCTTAATTTTGTATCTTCTCGAGATGATGAACAAAGAGGATGAT 372

XX 402 ACCAAGACCTCCAGCTGATGATTTGATGATGATGATTTGATGATGATGATGAT 461

XX 373 GAGGATGATGATTTTCCAGAGATGATGATGATGATGATGATGATGATGATGAT 432

XX 462 GCACAA 468

XX 433 GAAAAA 439


```

OY 250 AGAAAAGCTGGCTGGCCGCGGCTTACCAAGAGAGATATCAAGCCAGTGTGCTGTG 309
Db 411 NATCTGCCAGTCATGCGCAAGTTAACAAAGAAAGGSCAAGCTTAATGGCTTAGTG 352
OY 310 TGGACTTGTATPACTGAGAGAGACTGGAAAGGGATGAAGATGGAGCTGCTCATGTGG 369
Db 351 TCGACTTCAATPATATGGAAGAGCTGGGAAGATTCAGATGAAGACATGTCTAATTTTG 292
OY 370 AACATTATGCAGAGCTTTTGAAGAGTCTAG-----CACCAAGAGACCTCCACCTGCCA 423
Db 291 ATCGTTTCTCTGAGATGATGAACACATGGTGGTGTGATGAGATGTAGATTTTACCGAAG 232
OY 424 TGGATGATTTGGATGATGATTTCTGACAGTGTGATGATGCACAA 468
Db 231 TAGATGAGAGAGATGATGATTCACAAAGACAGTGTGATGATGAAAAA 187

```

Search completed: March 20, 2003, 02:46:12
 Job time : 244 secs